CN121648131A - 细胞内atp增强剂 - Google Patents

细胞内atp增强剂

Info

Publication number
CN121648131A
CN121648131A CN202511908836.6A CN202511908836A CN121648131A CN 121648131 A CN121648131 A CN 121648131A CN 202511908836 A CN202511908836 A CN 202511908836A CN 121648131 A CN121648131 A CN 121648131A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
use according
atp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511908836.6A
Other languages
English (en)
Chinese (zh)
Inventor
平冈美纪
冈本研
平野益治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
Nippon Chemiphar Co Ltd
University of Tokyo NUC
Original Assignee
SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
Nippon Chemiphar Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN, Nippon Chemiphar Co Ltd, University of Tokyo NUC filed Critical SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
Publication of CN121648131A publication Critical patent/CN121648131A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202511908836.6A 2020-12-08 2021-12-08 细胞内atp增强剂 Pending CN121648131A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020-203725 2020-12-08
JP2020203725 2020-12-08
CN202180082096.9A CN116528840B (zh) 2020-12-08 2021-12-08 细胞内atp增强剂
PCT/JP2021/045045 WO2022124325A1 (ja) 2020-12-08 2021-12-08 細胞内ａｔｐ増強剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180082096.9A Division CN116528840B (zh) 2020-12-08 2021-12-08 细胞内atp增强剂

Publications (1)

Publication Number Publication Date
CN121648131A true CN121648131A (zh) 2026-03-13

Family

ID=81973288

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511908836.6A Pending CN121648131A (zh) 2020-12-08 2021-12-08 细胞内atp增强剂
CN202180082096.9A Active CN116528840B (zh) 2020-12-08 2021-12-08 细胞内atp增强剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180082096.9A Active CN116528840B (zh) 2020-12-08 2021-12-08 细胞内atp增强剂

Country Status (8)

Country Link
US (1) US20240051971A1 (https=)
EP (1) EP4260860A4 (https=)
JP (1) JPWO2022124325A1 (https=)
KR (1) KR20230118083A (https=)
CN (2) CN121648131A (https=)
AU (1) AU2021398258A1 (https=)
CA (1) CA3201273A1 (https=)
WO (1) WO2022124325A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025258615A1 (ja) * 2024-06-12 2025-12-18 学校法人日本医科大学 運動機能向上剤、及びそれを含む医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0219354Y2 (https=) 1984-09-13 1990-05-29
FR2608045B1 (fr) * 1986-12-12 1990-03-02 Chauvin Laboratoires Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
DK1757610T3 (da) 2004-06-14 2011-08-01 Nippon Chemiphar Co Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor
CN101282934A (zh) * 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
ES2884123T3 (es) * 2013-03-15 2021-12-10 Xortx Therapeutics Inc Formulaciones de inhibidores de xantina oxidasa
US10413546B2 (en) * 2015-02-24 2019-09-17 National University Corporation Tottori University Drug for preventing and/or treating dementia
KR102600879B1 (ko) 2015-08-26 2023-11-09 가부시키가이샤 스타젠 세포 내 atp 증강제
JP6867142B2 (ja) 2016-11-17 2021-04-28 株式会社スタージェン パーキンソン症状改善用医薬
WO2018092911A1 (ja) 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤
JP6937134B2 (ja) * 2016-11-21 2021-09-22 株式会社スタージェン 細胞内ａｔｐ増強剤
JP6966840B2 (ja) 2017-01-24 2021-11-17 株式会社スタージェン 神経変性疾患の改善用医薬
JP2018135278A (ja) 2017-02-20 2018-08-30 株式会社スタージェン 循環器疾患及び／又はミトコンドリア病の改善用医薬
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP2021127289A (ja) 2018-04-27 2021-09-02 日本ケミファ株式会社 縮合ピリミジン誘導体
WO2020246528A1 (ja) * 2019-06-04 2020-12-10 日本ケミファ株式会社 痛風又は高尿酸血症の治療薬
CN110156131A (zh) 2019-06-17 2019-08-23 厦门翟苑日用品有限公司 一种幼儿园健康饮用水集中处理器

Also Published As

Publication number Publication date
CN116528840A (zh) 2023-08-01
AU2021398258A9 (en) 2024-02-08
CA3201273A1 (en) 2022-06-16
US20240051971A1 (en) 2024-02-15
EP4260860A4 (en) 2024-11-06
KR20230118083A (ko) 2023-08-10
CN116528840B (zh) 2026-01-06
WO2022124325A1 (ja) 2022-06-16
EP4260860A1 (en) 2023-10-18
JPWO2022124325A1 (https=) 2022-06-16
WO2022124325A8 (ja) 2023-05-11
AU2021398258A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
US20090142395A1 (en) Deferasirox pharmaceutical compositions
US12343430B2 (en) Methods of improving pharmaceutical substance solubilization and products thereof
IL296355A (en) Oral hsp90 inhibitor formulations and related methods
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
EP3718548B1 (en) Solid dispersion
CN116528840B (zh) 细胞内atp增强剂
JPWO2006087919A1 (ja) 難水溶性物質含有微細化組成物
JP2025061775A (ja) 痛風又は高尿酸血症の治療薬
US10391178B2 (en) Premix of crystalline raltegravir potassium salt and a process for the preparation thereof
CN113214206B (zh) 橙皮素与甜菜碱共晶物b及制备方法和其组合物与用途
HK40073463B (en) Therapeutic for gout or hyperuricemia
HK40073463A (en) Therapeutic for gout or hyperuricemia
EP3981470A1 (en) Enteric-coated preparation comprising xanthine oxidase inhibitor
WO2024211881A1 (en) Rimegepant suspension
HK40096982A (zh) 包含美洛昔康的医药组成物
BRPI0607372B1 (pt) Medicamento destinado à administração oral, compreendendo um inibidor da ciclooxigenase-2, e método de preparação do mesmo
KR20050016444A (ko) 안 질환 치료를 위한 로플루밀라스트의 안과학적 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination